![](https://cdn.sanity.io/images/0vv8moc6/onclive/8a11ff6f8743c5fc9ebd930a22c3fe674e158263-200x200.jpg?fit=crop&auto=format)
Neoadjuvant Therapy Selection: Are Abbreviated Regimens an Option in HER2+ Breast Cancer?
Staying within the standard of care (SOC), abbreviated neoadjuvant regimens are not yet ready for primetime in HER2-positive breast cancer, according to Adrienne G. Waks, MD, who added that data from the ongoing phase 2 CompassHER2-pCR trial (NCT04266249) …